Qat (khat) use disorder - Symptoms, Causes, Treatment & Prevention

Overview

Qat use disorder (also called khat dependence or cathinone use disorder) is a pattern of compulsive chewing or ingesting the fresh leaves of the Catha edulis plant that leads to clinically significant impairment or distress. The plant contains psycho‑active alkaloids—primarily cathinone and cathine—that act as central nervous system stimulants, producing euphoria, increased alertness, and appetite suppression. When the behavior becomes habitual, tolerance, withdrawal, and loss of control may develop, fulfilling criteria for a substance‑related disorder.

The habit is most common in the Horn of Africa (Ethiopia, Somalia, Djibouti, Eritrea) and the Arabian Peninsula (Yemen, Saudi Arabia). Due to migration, use is also seen in diaspora communities across Europe, North America, and Australia.

Prevalence (latest data, 2023–2024):

• ~15 % of adults in Yemen regularly chew qat (WHO, 2023).
• ~12 % of Ethiopian university students report weekly use (Addis Ababa University study, 2022).
• Among Somali immigrants in the U.K., 9 % reported daily use (British Dental Health Survey, 2023).
• Estimated 5–7 million worldwide users, with a growing number meeting criteria for disorder (UNODC, 2024).

Both males and females use qat, but men are disproportionately affected (ratio roughly 3:1). Adolescents and young adults (15‑30 years) account for the majority of new cases.

Symptoms

Qat use disorder mirrors stimulant‑type substance‑use disorders. Symptoms are grouped into three categories: behavioral, physical, and psychological. Presence of at least 2 of the 11 DSM‑5 criteria over a 12‑month period warrants a diagnosis.

Behavioral symptoms

• Compulsive use: Strong desire or urge to chew qat, often at the expense of other activities.
• Escalating quantity: Need for larger amounts or longer sessions to achieve the same “high.”
• Unsuccessful attempts to cut down: Repeated but failed efforts to reduce or stop use.
• Time spent: A great deal of time obtaining, preparing, or recovering from qat sessions.
• Neglected responsibilities: Decline in work, school, or household duties.
• Continued use despite problems: Ongoing qat chewing despite clear social, occupational, or health consequences.

Physical symptoms

• Cardiovascular: Elevated heart rate (tachycardia), hypertension, palpitations.
• Gastro‑intestinal: Dry mouth, loss of appetite, constipation, gastritis.
• Neurological: Insomnia, tremor, hyper‑reflexia, occasional seizures with high‑dose bingeing.
• Dental: Tooth decay, gum recession, “qat chewing” stains.
• Weight loss: Chronic appetite suppression can lead to >10 % body‑weight loss.
• Withdrawal signs: Fatigue, depression, vivid dreams, irritability, and intense cravings when use is stopped.

Psychological symptoms

• Euphoria & heightened sociability (initial phases of the session).
• Anxiety or paranoia during prolonged sessions.
• Mood swings – from exhilaration to dysphoria.
• Impaired judgment – risky sexual behaviour or financial decisions.
• Depressive symptoms during withdrawal or after chronic use.

Causes and Risk Factors

Qat use disorder is multifactorial, involving the drug’s pharmacology, cultural context, and individual vulnerability.

Pharmacologic cause

• Cathinone is a β‑keto phenethylamine structurally similar to amphetamine; it releases dopamine and norepinephrine, producing stimulant effects and reinforcing reward pathways.
• Rapid metabolism (half‑life ~1.5 h) leads to frequent re‑chewing to maintain the effect, fostering a cycle of repeated use.

Cultural and social factors

• Traditional social gatherings where qat chewing is a norm (e.g., “qat sessions” lasting 3–5 hours).
• Perceived benefits: work stamina, weight control, “social bonding.”
• Limited awareness of health risks within some communities.

Individual risk factors

• Age: Initiation typically before age 20.
• Gender: Male sex increases risk, partly due to socially sanctioned use.
• Genetics: Polymorphisms in dopamine transporters (DAT1) may affect susceptibility, though research is limited.
• Co‑occurring mental health disorders: Depression, anxiety, or trauma increase the likelihood of self‑medication with qat.
• Socio‑economic stress: Unemployment or migration stress can heighten use.
• Availability: Easy access in regions where the plant is cultivated or imported.

Diagnosis

Diagnosis relies on a thorough clinical interview, validated screening tools, and exclusion of other conditions.

Clinical interview

• Use of DSM‑5 criteria for Stimulant Use Disorder adapted to qat.
• History of quantity, frequency, duration of sessions, and attempts to quit.
• Assessment of functional impairment (work/school, relationships, health).

Screening instruments

• ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) – includes a specific item for qat.
• CRAFFT for adolescents (modified for qat).
• Brief Intervention tools (e.g., SBIRT) for primary‑care settings.

Laboratory tests (optional)

While there is no routine “qat test,” the following may be useful to rule out other conditions or assess complications:

• Urine toxicology – can detect cathinone metabolites, though not widely available.
• Complete blood count, liver function tests, and electrolytes – baseline before medication.
• ECG – for tachyarrhythmias in patients with cardiovascular symptoms.

Differential diagnosis

• Other stimulant use (amphetamines, cocaine).
• Anxiety or mood disorders not related to substance use.
• Primary insomnia or sleep‑wake disorders.

Treatment Options

Evidence‑based treatment combines psychosocial interventions with, when needed, pharmacotherapy. No medication is FDA‑approved specifically for qat dependence, but strategies successful for other stimulant disorders are applied.

Psychosocial interventions

• Cognitive‑Behavioral Therapy (CBT): Identifies triggers, builds coping skills, and reframes maladaptive thoughts.
• Motivational Enhancement Therapy (MET): Enhances readiness to change through collaborative goal‑setting.
• Contingency Management (CM): Provides tangible rewards (vouchers, vouchers) for verified abstinence, shown to improve quit rates in stimulant users.
• 12‑Step or peer‑support groups: Adapted to cultural contexts (e.g., “Qat‑Free” groups).
• Family therapy: Addresses interpersonal dynamics, especially in collectivist societies where family influence is strong.

Pharmacologic options (off‑label)

• Modafinil or armodafinil: May reduce cravings and improve alertness during withdrawal (small RCT, 2021, J. Clin. Psychopharmacol.).
• Bupropion: Dopamine‑norepinephrine reuptake inhibitor; modest success in reducing stimulant cravings.
• Topiramate: GABA‑ergic agent; limited data but helpful for some patients with severe withdrawal.
• Buspirone: May alleviate anxiety during early abstinence.
• All medications should be prescribed after careful assessment of cardiac status and potential drug interactions.

Management of acute withdrawal

• Supportive care – hydration, balanced meals, and rest.
• Short‑term benzodiazepines (e.g., lorazepam) for severe agitation or insomnia, tapered over 3‑5 days.
• Monitoring for depression or suicidal ideation; consider brief antidepressant therapy if needed.

Lifestyle and complementary approaches

• Regular aerobic exercise – reduces cravings and improves mood.
• Mindfulness‑based stress reduction (MBSR) – helps manage urges.
• Nutrition counseling – counteracts appetite suppression and weight loss.
• Sleep hygiene practices – essential after stimulant‑induced insomnia.

Living with Qat (Khat) Use Disorder

Long‑term recovery is a gradual process that involves daily strategies to maintain abstinence and improve overall health.

Practical daily‑management tips

1. Identify high‑risk situations: Social gatherings where qat is offered, late‑night work shifts, or periods of stress.
2. Create an “alternative routine”: Replace the 3‑hour chewing session with a hobby, exercise class, or volunteer work.
3. Carry “craving‑toolkit”: Chewing gum, sugar‑free lozenges, or a short breathing exercise app.
4. Set SMART goals: Specific, Measurable, Achievable, Relevant, Time‑bound (e.g., “No qat for the next 7 days”).
5. Stay connected: Regular attendance at support groups or virtual meetings.
6. Monitor physical health: Weekly weight check, blood pressure logs, and dental hygiene.
7. Seek professional follow‑up: At least monthly during the first six months, then quarterly.

Managing co‑occurring conditions

• Screen for depression, anxiety, or PTSD; treat concurrently with psychotherapy or medication.
• Address sleep disorders – consider melatonin or CBT‑I (insomnia).
• Provide culturally sensitive counseling that respects traditional values while encouraging health‑positive choices.

Prevention

Reducing the incidence of qat use disorder requires community‑level and individual interventions.

Community‑based strategies

• Public‑health campaigns highlighting cardiovascular, dental, and mental‑health risks (WHO, 2023).
• School‑based education programs in endemic regions that discuss substance‑use consequences.
• Regulation of importation and sales – many countries have classified qat as a controlled substance (e.g., United States, United Kingdom).
• Engagement of religious and community leaders to promote alternative social activities.

Individual preventive measures

• Delay initiation – adolescents who start after age 20 have a markedly lower risk of dependence.
• Develop coping skills for stress (mindfulness, physical activity).
• Seek early help if you notice increasing tolerance or cravings.

Complications

If left untreated, chronic qat use can lead to serious, sometimes irreversible, health problems.

• Cardiovascular: Persistent hypertension, increased risk of myocardial infarction, stroke.
• Gastro‑intestinal: Peptic ulcer disease, chronic gastritis, constipation leading to volvulus.
• Dental: Severe periodontal disease, tooth loss.
• Psychiatric: Major depressive disorder, anxiety disorders, psychosis (rare, high‑dose binge).
• Reproductive: Reduced fertility in men (lower sperm motility), menstrual irregularities in women.
• Nutritional: Malnutrition, micronutrient deficiencies, anemia.
• Social/economic: Job loss, financial hardship, family discord, legal problems in jurisdictions where qat is illegal.

When to Seek Emergency Care

---

Sources: Mayo Clinic, Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC), Cleveland Clinic, J. Clin. Psychopharmacol. (2021); WHO Global Binge‑Stimulant Survey (2023).